CORPORATE MEDIA RELEASE
UK HIGH COURT OF JUSTICE RULES ENDOCUFF® AND ENDOCUFF VISION® PATENTS AND DESIGN RIGHTS TO BE VALID AND INFRINGED
AMSTERDAM. The Netherlands. Friday 23 February. 14:00 CET. Arc Medical Design Limited, a subsidiary of Norgine B.V., today announced that the High Court of Justice England and Wales, Patents Court ruled that ENDOCUFF® and ENDOCUFF VISION® UK national and UK(EP) patents (as amended) are valid and infringed by Cantel’s AmplifEYE® endoscopic device, and key design rights are valid and infringed by AmplifEYE® the patent and design rights had been challenged by Cantel Medical (UK) Limited and Cantel (UK) Limited.
Peter Martin, COO of Norgine and Chair of the Arc Medical Design Limited Board said: “We welcome the judgement and our resounding success, recognising the strong protection for both ENDOCUFF® and ENDOCUFF VISION®. This decision validates our confidence in the intellectual property portfolio protecting our products. We will always vigorously defend our intellectual property and will initiate legal proceedings where appropriate.”
ENDOCUFF VISION® is a single use device attached at the end of the colonoscope that gives an optimal view of the entire colon by retracting folds during withdrawal.
Notes to Editors:
About the UK Case No. HP-2016-000047
On Friday 23 February 2018 the High Court of Justice England and Wales, Patents Court ruled that:Arc Medical Design Limited won on all counts:
- Arc Medical Design Limited’s ENDOCUFF and ENDOCUFF VISION UK national patent 2478081 and UK(EP) patent 2575590, as amended, are valid and infringed;
- its ENDOCUFF VISION Registered Community Design 002523191-0001 is valid and infringed, its ENDOCUFF Registered Community Design 001856121-0001 is valid but not infringed; and
- its UK unregistered design rights in ENDOCUFF and ENDOCUFF VISION will be infringed from the date of the judgment.
- The judgment is for the UK market.
About ENDOCUFF VISION®
ENDOCUFF VISION® significantly improves adenoma detection rate and colorectal cancer detection during colonoscopy in bowel cancer screening patients.[i]
Adenoma detection rate is the most important marker of colonoscopy quality to help detect anomalies and colorectal cancer.
Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net sales were EUR 345 million, up 17 per cent.
Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.
Norgine specialises in gastroenterology, hepatology, cancer and supportive care.
Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.
For more information, please visit www.norgine-it-t1.wmno.uk
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
NORGINE and the sail logo are registered trademarks of the Norgine group of companies.
About Arc Medical Design Ltd.
Providing award-winning and innovative products worldwide, Arc Medical is leading the way in increasing Adenoma Detection Rates (ADR) and improving retrieval methods.
As a clinician driven company, Arc Medical is uniquely positioned to understand the needs of those working in the gastro-intestinal sector and strives to improve physician experience and patient outcome.
ENDOCUFF and ENDOCUFF VISION are registered trademarks of Arc Medical Design Ltd.
Isabelle Jouin, T: +44 (0)1895 453643
Follow us @norgine
[i] Ngu WS, et al. Gut 2018;66:1–9. doi:10.1136/gutjnl-2017-314889